查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2014906

液態生物檢體市場：按生物標記、檢體、類型、技術、適應症、最終用戶和應用分類——2026-2032年全球市場預測

Liquid Biopsy Market by Biomarkers, Sample, Type, Technology, Indication, End-User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，液態生物檢體市場價值將達到 75.2 億美元，到 2026 年將成長至 84.4 億美元，到 2032 年將達到 173.1 億美元，複合年成長率為 12.63%。

主要市場統計數據
基準年 2025 75.2億美元
預計年份：2026年 84.4億美元
預測年份 2032 173.1億美元
複合年成長率 (%) 12.63%

為產業相關人員權威介紹液態生物檢體和精準醫療/腫瘤診斷的變革潛力。

液態生物檢體是診斷醫學領域的模式轉移，它透過分析體液中的循環生物標記物，提供了一種侵入性較小的途徑來了解腫瘤的生物學特徵。與需要手術切除且有相關風險的傳統切片檢查不同，液態生物檢體利用循環腫瘤DNA、細胞和囊泡來即時獲取動態分子資訊。這種方法與日益興起的「精準腫瘤學」理念相契合，精準腫瘤學可以透過最佳化治療方案以匹配個別分子特徵，從而顯著改善患者的治療效果。

探索透過技術突破、監管進步和策略性產業合作，重新定義液態生物檢體格局的關鍵變化。

在次世代定序、數位PCR和新型生物資訊流程等突破性技術的推動下，液態切片領域正以前所未有的速度發展。這些技術進步顯著提高了分析物的檢測敏感度和特異性，使得在癌症早期階段識別罕見的循環腫瘤DNA片段成為可能。同時，主要市場的監管機構也開始實施更有效率的伴隨診斷核准流程，這反映了他們對液態切片檢測的臨床效用和可重複性的信心。

評估 2025 年美國關稅對液態生物檢體供應鏈、定價結構和全球研究合作的累積影響。

2025年1月1日，美國對進口診斷劑和設備加徵新關稅，加劇了跨境供應鏈的複雜性。新增關稅提高了關鍵耗材的接收成本，迫使製造商和實驗室合作夥伴重新評估其籌資策略和庫存模式。對於依賴專用試劑的公司而言，尋找國內替代供應商並簽訂長期合約已成為維持利潤率和避免服務中斷的關鍵挑戰。

透過多方面的細分，包括生物標記、檢體、檢測類型、技術、適應症、應用和最終用戶趨勢，可以獲得關鍵見解。

基於生物標記分類的分割揭示了成熟分析物和新興分析物之間的相互作用。遊離細胞DNA (cfDNA) 因其與腫瘤負荷和突變譜的明確相關性，仍是臨床檢測的基礎。同時，循環性腫瘤細胞(CTC) 為表現型分析開啟了新的機會。循環腫瘤DNA (ctDNA) 技術的出現使得即時監測抗藥性突變成為可能，而對細胞外囊泡 (EV) 的研究則為RNA轉運和蛋白質組學特徵的研究開闢了新的領域。

了解影響美洲、歐洲、中東和非洲以及亞太市場液態生物檢體引入和創新的區域趨勢。

美洲地區憑藉其先進的法規結構和大規模的臨床應用，繼續發揮主導作用。各國政府針對癌症篩檢和價值醫療的舉措，正在加速推進保險報銷方面的討論，並推動大學醫院和社區醫院更廣泛地應用相關技術。此外，本地診斷公司與國際技術供應商之間的策略合作，正在加強供應鏈，並擴大區域內尖端檢測技術的普及範圍。

本分析考察了快速發展的液態生物檢體生態系統中主要企業的策略定位、競爭力和市場貢獻。

領先的診斷和生物技術公司正透過差異化的平台、策略性收購和廣泛的智慧財產權組合來鞏固其市場地位。擁有完善檢測網路的成熟公司正利用豐富的臨床檢驗數據來拓展其檢測服務，而純粹的創新者則專注於獨特的化學技術和先進的生物資訊學，以期搶佔市場先機。

制定具有前瞻性的策略和可操作的建議，使行業相關人員能夠充分利用液態生物檢體的進步和市場機會。

為了應對不斷變化的液態生物檢體領域，行業相關人員應優先投資於靈活的檢測架構，以支援靶向和廣譜檢測應用。這種方法能夠靈活應對新出現的生物標記和監管政策的變化。將多組體學功能整合到現有工作流程中，可以提高診斷準確性，並更深入了解腫瘤異質性。

概述了嚴格的調查方法，包括數據收集、分析和檢驗，以全面涵蓋液態生物檢體領域。

為確保報告的可靠性和可信度，本報告採用了嚴格的一手和二手調查方法相結合的方式。首先，我們進行了廣泛的二手研究，涵蓋同行評審期刊、臨床試驗註冊資訊、專利申請、監管文件和白皮書，從而為技術和臨床理解奠定了全面的基礎。

本文總結了液態生物檢體創新在推進精準診斷和患者照護的策略意義、未來前景和永續價值。

液態生物檢體已成為現代診斷實踐的基石，彌合了分子層面洞察與個人化患者管理之間的鴻溝。它能夠透過非侵入性取樣檢測和監測疾病，為早期療育、最佳化治療和長期後續觀察開闢了新的途徑。隨著技術平台的日趨成熟，液態生物檢體正從小眾研究應用轉向主流臨床應用。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：按生物標記分類的液態生物檢體市場

  • 細胞中的遊離DNA
  • 循環性腫瘤細胞
  • 循環腫瘤DNA
  • 細胞外囊泡

第9章 按檢體類型分類的液態生物檢體市場

  • 血液衍生的
  • 尿液來源的

第10章：液態生物檢體市場：按類型分類

  • 檢測試劑盒
  • 裝置
  • 服務

第11章：液態生物檢體市場：依技術分類

  • 利用NGS進行多基因平行分析
  • 利用PCR微陣列進行單一基因分析

第12章：液態生物檢體市場：依適應症分類

  • 癌症治療
    • 乳癌
    • 結腸癌
    • 肺癌
    • 惡性黑色素瘤
    • 攝護腺癌
  • 非癌症適應症

第13章：液態生物檢體市場：依最終用戶分類

  • 學術和研究機構
  • 臨床診斷檢查室
  • 醫院
  • 臨床檢查室

第14章：液態生物檢體市場：依應用領域分類

  • 早期癌症篩檢
  • 復發監測
  • 治療方法方案
  • 治療監測

第15章：液態生物檢體市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章：液態生物檢體市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章：液態生物檢體市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章：美國液態生物檢體市場

第19章：中國液態生物檢體市場

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • ANGLE PLC
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Biocartis NV
  • Danaher Corporation
  • DiaCarta, Inc.
  • Dxcover Limited
  • Epic Sciences Inc.
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • GENCURIX
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Labcorp Holdings Inc.
  • Laboratory Dr. med. Pachmann
  • Lucence Health Inc.
  • LungLife AI, Inc.
  • MDxHealth SA
  • Menarini Silicon Biosystems SpA
  • Merck KGaA
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • NeoGenomics Laboratories, Inc.
  • OncoDNA SA
  • PerkinElmer, Inc.
  • Personalis, Inc.
  • QIAGEN NV
  • SAGA Diagnostics AB
  • Strand Life Sciences Pvt Ltd.
  • Sysmex Corporation
  • Tempus AI, Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-43470FC608C8

The Liquid Biopsy Market was valued at USD 7.52 billion in 2025 and is projected to grow to USD 8.44 billion in 2026, with a CAGR of 12.63%, reaching USD 17.31 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.52 billion
Estimated Year [2026] USD 8.44 billion
Forecast Year [2032] USD 17.31 billion
CAGR (%) 12.63%

An authoritative introduction to liquid biopsy and its transformative potential in precision medicine and oncology diagnostics for industry stakeholders

Liquid biopsy represents a paradigm shift in diagnostic medicine by offering a minimally invasive window into tumor biology through the analysis of circulating biomarkers in bodily fluids. Unlike conventional tissue biopsies that necessitate surgical extraction and carry procedural risks, liquid biopsy harnesses circulating tumor DNA, cells, and vesicles to capture dynamic molecular information in real time. This approach aligns with the growing emphasis on precision oncology, where tailoring therapeutic regimens to individual molecular profiles can dramatically improve patient outcomes.

As cancer incidence continues to rise globally, healthcare systems are under pressure to deliver cost-effective, rapid diagnostics that minimize patient discomfort without compromising accuracy. Liquid biopsy addresses these demands by enabling serial monitoring of disease progression, early detection of minimal residual disease, and the identification of actionable mutations that guide targeted therapies. Moreover, its application extends beyond oncology into transplant medicine, prenatal screening, and infectious disease monitoring, positioning liquid biopsy as a versatile tool for modern clinical practice.

Stakeholders across pharmaceutical, diagnostic, and research sectors are now evaluating how to integrate liquid biopsy into existing workflows and regulatory pathways. With technological advances driving down assay time and costs, liquid biopsy is poised to become a standard component of patient management. In the following sections, we explore the transformative forces reshaping this landscape, the implications of recent policy changes, and the strategic insights that will guide industry leaders forward.

Exploring the pivotal shifts redefining the liquid biopsy landscape through technological breakthroughs regulatory progress and strategic industry collaborations

The liquid biopsy landscape is evolving at an unprecedented pace, propelled by breakthroughs in next-generation sequencing, digital PCR, and novel bioinformatics pipelines. These technological advancements have significantly increased the sensitivity and specificity of analyte detection, enabling the identification of rare circulating tumor DNA fragments at early stages of cancer. Concurrently, regulatory agencies across key markets have begun to issue more streamlined approval pathways for companion diagnostics, reflecting confidence in the clinical utility and reproducibility of liquid biopsy assays.

At the same time, strategic collaborations between diagnostic manufacturers, academic centers, and pharmaceutical firms are accelerating assay validation and broadening the scope of clinical studies. Such partnerships are fostering the co-development of targeted panels aligned with emerging targeted therapies, thereby integrating diagnostics directly into the drug development lifecycle. Meanwhile, decentralized testing models-ranging from point-of-care platforms to patient-collected sampling kits-are democratizing access and supporting remote monitoring initiatives.

Collectively, these forces are redefining the competitive dynamics of the liquid biopsy domain. Incumbent laboratory providers are investing in proprietary platforms to maintain differentiation, while nimble start-ups continue to innovate assay chemistries and data analytics. Looking ahead, convergence around multi-omics integration and standardized reporting frameworks will further solidify liquid biopsy's role as a cornerstone of personalized care.

Assessing the cumulative repercussions of the 2025 United States tariffs on liquid biopsy supply chains pricing structures and global research collaborations

On January 1, 2025, new U.S. tariffs on imported diagnostic reagents and instrumentation took effect, introducing a layer of complexity for cross-border supply chains. The added duties have increased landed costs for core consumables, prompting manufacturers and laboratory partners to reassess sourcing strategies and inventory models. For companies reliant on specialized reagents, securing alternative domestic suppliers or negotiating long-term contracts has become a critical objective to contain margins and avoid service disruptions.

The ripple effects extend into pricing structures, as laboratories pass incremental expenses to payers and patients, potentially impacting adoption rates in price-sensitive segments. To mitigate these pressures, several industry players have begun exploring localized manufacturing solutions, including establishing regional production hubs and partnering with contract development organizations. In parallel, increased collaboration with customs authorities and trade associations has enabled more efficient classification and duty minimization, offering relief to stakeholders navigating the evolving tariff landscape.

Despite these headwinds, many organizations view the 2025 tariffs as a catalyst to strengthen domestic supply resilience and foster innovation in reagent design. By investing in robust regional capabilities and diversifying supplier networks, the industry anticipates a more balanced cost structure over the long term, ultimately supporting sustainable growth and uninterrupted patient access.

Deriving critical insights from multifaceted segmentation of biomarkers samples assay types technologies indications applications and end-user dynamics

Segmentation by biomarker class reveals the interplay between mature and emerging analytes. Cell-free DNA continues to anchor clinical assays due to its well-established correlation with tumor burden and mutational profiling, while circulating tumor cells unlock opportunities for phenotypic analysis. The advent of circulating tumor DNA technologies enables real-time monitoring of resistance mutations, and the exploration of extracellular vesicles is opening new research frontiers around RNA cargo and proteomic signatures.

When considering sample origin, blood-based tests dominate current workflows because of established venipuncture protocols and high analyte yield. However, urine-based assays are gaining traction as a noninvasive alternative for longitudinal screening, particularly in urological and genitourinary indications. Advances in sample stabilization and extraction methods are narrowing performance gaps, setting the stage for wider clinical adoption of diversified fluid matrices.

In terms of product taxonomy, assay kits form the backbone of commercial offerings by delivering standardized workflows that simplify laboratory implementation. Instruments add value through automation and throughput optimization, while services encompass bespoke assay development, data interpretation, and clinical reporting. On the technology front, multi-gene parallel analysis using next-generation sequencing is prized for its multiplexing capacity and depth of coverage, whereas single-gene analysis via PCR microarrays maintains a strong presence in targeted mutation detection due to rapid turnaround.

Indication-driven segmentation underscores the primacy of cancer applications, with breast, colorectal, lung, melanoma, and prostate cancers accounting for the majority of clinical validation studies. Non-cancer indications are expanding into areas such as organ transplant rejection monitoring and prenatal aneuploidy screening. Among end-users, academic and research centers spearhead exploratory studies, while clinical diagnostic laboratories, hospitals, and physician office labs drive routine testing volumes. Finally, application segmentation reveals a balanced portfolio of early cancer screening initiatives, recurrence monitoring protocols, therapy selection assays, and treatment monitoring programs, reflecting the multifaceted utility of liquid biopsy in patient management.

Uncovering regional dynamics shaping liquid biopsy adoption and innovation across the Americas Europe Middle East Africa and Asia Pacific markets

The Americas continue to lead with advanced regulatory frameworks and high-volume clinical adoption. Government initiatives focusing on cancer screening and value-based care have accelerated reimbursement discussions, enabling broader uptake in both academic medical centers and community hospitals. Moreover, strategic partnerships between local diagnostic companies and international technology providers have fortified supply chains and expanded regional access to cutting-edge assays.

Europe, Middle East, and Africa present a heterogeneous landscape marked by diverse regulatory regimes and reimbursement environments. In Western Europe, centralized health technology assessments and national screening programs drive standardization, whereas emerging markets in Eastern Europe, the Middle East, and Africa are gradually integrating liquid biopsy into oncology networks through pilot projects and center-of-excellence collaborations. Cross-border data sharing and harmonized clinical guidelines remain key enablers of sustainable growth across these jurisdictions.

Asia-Pacific is characterized by rapid market expansion underpinned by significant public health investments and rising cancer incidence. Government funding for cancer genomics and domestic manufacturing incentives have catalyzed indigenous assay development. Collaborative research between regional academic institutions and global diagnostic firms is intensifying, while the rollout of digital pathology and telemedicine platforms supports remote sample collection and result dissemination, extending the reach of liquid biopsy solutions.

Analyzing strategic positioning competitive strengths and market contributions of leading corporations in the rapidly evolving liquid biopsy ecosystem

Leading diagnostic and biotechnology companies are positioning themselves through differentiated platforms, strategic acquisitions, and expansive intellectual property portfolios. Legacy players with established laboratory networks are leveraging deep clinical validation data to extend their assay menus, while pure-play innovators focus on proprietary chemistries and advanced bioinformatics to achieve early market entry.

Collaborative alliances between pharmaceutical companies and diagnostic developers are accelerating the co-development of companion diagnostics tailored to specific targeted therapies. Start-ups are forging partnerships with contract research organizations to streamline multicenter clinical trials, ensuring robust evidence generation and regulatory alignment. At the same time, instrument manufacturers are integrating connectivity features and cloud-based data analytics into their platforms, enhancing operational efficiency and facilitating seamless integration with laboratory information systems.

Beyond technology differentiation, corporate strategies are increasingly oriented toward geographic expansion through regional sales networks and production hubs. By aligning global R&D pipelines with localized commercialization strategies, leading companies are building scalable models that address diverse regulatory requirements and market access challenges.

Crafting forward-looking strategies and practical recommendations for industry stakeholders to capitalize on liquid biopsy advancements and market opportunities

To navigate the evolving liquid biopsy environment, industry stakeholders should prioritize investment in flexible assay architectures that support both targeted and broad-panel applications. This approach ensures agility in responding to emerging biomarkers and regulatory shifts. Integrating multi-omics capabilities into existing workflows will enhance diagnostic accuracy and provide richer insights into tumor heterogeneity.

Building resilient supply chains through regional manufacturing partnerships and dual-sourcing agreements can mitigate exposure to trade policy fluctuations. Organizations should also establish cross-functional teams that unite regulatory, commercial, and scientific experts to streamline product approvals and reimbursement negotiations. Collaborative initiatives with payers and healthcare providers will strengthen the value proposition by demonstrating real-world clinical utility and cost savings.

Digital transformation should remain a strategic priority, with investments in cloud-native analytics, artificial intelligence-driven variant interpretation, and telehealth-enabled sample collection. These technologies will support decentralized testing models and personalized patient engagement. Finally, fostering open innovation through consortiums and public-private partnerships will accelerate the validation of novel analytes and drive the harmonization of reporting standards, reinforcing liquid biopsy's role in precision medicine.

Outlining rigorous research methodology encompassing data collection analysis validation to ensure comprehensive coverage of the liquid biopsy domain

This report's methodology integrates a rigorous blend of secondary and primary research to ensure robustness and credibility. Initially, extensive secondary research was conducted, encompassing peer-reviewed journals, clinical trial registries, patent filings, regulatory publications, and white papers to establish a comprehensive foundation of technical and clinical understanding.

Primary research was conducted through in-depth interviews with senior executives, laboratory directors, and key opinion leaders across diagnostics, pharmaceutical, and academic sectors. These expert dialogues provided nuanced perspectives on assay development, regulatory strategy, and commercialization challenges. Data triangulation techniques validated qualitative insights against proprietary databases and financial disclosures to reinforce accuracy.

Quantitative analysis involved mapping product pipelines, technology adoption metrics, and regional deployment patterns. Key variables were cross-referenced with public health statistics and reimbursement schedules to contextualize application potential. Validation workshops with external advisors and technical specialists were organized to resolve discrepancies and refine assumptions.

Collectively, this multi-layered approach delivers a holistic view of the liquid biopsy domain, balancing empirical evidence with expert interpretation to guide strategic decision-making.

Summarizing the strategic significance future outlook and enduring value of liquid biopsy innovations for advancing precision diagnostics and patient care

Liquid biopsy has emerged as a cornerstone of modern diagnostic practice, bridging the gap between molecular insights and personalized patient management. Its capacity to detect and monitor disease through noninvasive sampling unlocks new avenues for early intervention, treatment optimization, and long-term surveillance. As technology platforms mature, liquid biopsy is transitioning from niche research applications to mainstream clinical adoption.

Strategically, stakeholders who align their portfolios with the evolving landscape-incorporating flexible assay designs, resilient supply chains, and digital innovation-will be best positioned to capitalize on market opportunities. Continued collaboration across industry, academia, and regulatory bodies will drive the standardization of workflows and reimbursement frameworks, further reducing barriers to implementation.

Looking ahead, the integration of liquid biopsy with complementary diagnostics and therapeutic modalities promises to accelerate the shift toward truly individualized medicine. By embracing a data-driven, patient-centered approach, industry leaders can unlock significant clinical and commercial value, reinforcing liquid biopsy's role as a transformative force in healthcare.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Liquid Biopsy Market, by Biomarkers

  • 8.1. Cell-free DNA
  • 8.2. Circulating Tumor Cells
  • 8.3. Circulating Tumor DNA
  • 8.4. Extracellular Vesicles

9. Liquid Biopsy Market, by Sample

  • 9.1. Blood Based
  • 9.2. Urine Based

10. Liquid Biopsy Market, by Type

  • 10.1. Assay Kits
  • 10.2. Instruments
  • 10.3. Services

11. Liquid Biopsy Market, by Technology

  • 11.1. Multi-gene Parallel Analysis using NGS
  • 11.2. Single-gene Analysis using PCR Microarrays

12. Liquid Biopsy Market, by Indication

  • 12.1. Cancer Indication
    • 12.1.1. Breast Cancer
    • 12.1.2. Colorectal Cancer
    • 12.1.3. Lung Cancer
    • 12.1.4. Melanoma
    • 12.1.5. Prostate Cancer
  • 12.2. Non-Cancer Indication

13. Liquid Biopsy Market, by End-User

  • 13.1. Academic & Research Centers
  • 13.2. Clinical Diagnostic Laboratories
  • 13.3. Hospitals
  • 13.4. Physician's Office Laboratories

14. Liquid Biopsy Market, by Application

  • 14.1. Early Cancer Screening
  • 14.2. Recurrence Monitoring
  • 14.3. Therapy Selection
  • 14.4. Treatment Monitoring

15. Liquid Biopsy Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Liquid Biopsy Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Liquid Biopsy Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Liquid Biopsy Market

19. China Liquid Biopsy Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. ANGLE PLC
  • 20.6. Bio-Rad Laboratories, Inc.
  • 20.7. Bio-Techne Corporation
  • 20.8. Biocartis NV
  • 20.9. Danaher Corporation
  • 20.10. DiaCarta, Inc.
  • 20.11. Dxcover Limited
  • 20.12. Epic Sciences Inc.
  • 20.13. Exact Sciences Corporation
  • 20.14. F. Hoffmann-La Roche Ltd.
  • 20.15. GENCURIX
  • 20.16. Guardant Health, Inc.
  • 20.17. Illumina, Inc.
  • 20.18. Labcorp Holdings Inc.
  • 20.19. Laboratory Dr. med. Pachmann
  • 20.20. Lucence Health Inc.
  • 20.21. LungLife AI, Inc.
  • 20.22. MDxHealth SA
  • 20.23. Menarini Silicon Biosystems SpA
  • 20.24. Merck KGaA
  • 20.25. Myriad Genetics, Inc.
  • 20.26. Natera, Inc.
  • 20.27. NeoGenomics Laboratories, Inc.
  • 20.28. OncoDNA SA
  • 20.29. PerkinElmer, Inc.
  • 20.30. Personalis, Inc.
  • 20.31. QIAGEN N.V.
  • 20.32. SAGA Diagnostics AB
  • 20.33. Strand Life Sciences Pvt Ltd.
  • 20.34. Sysmex Corporation
  • 20.35. Tempus AI, Inc.
  • 20.36. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL LIQUID BIOPSY MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL LIQUID BIOPSY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL LIQUID BIOPSY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CELL-FREE DNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CELL-FREE DNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CELL-FREE DNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL LIQUID BIOPSY MARKET SIZE, BY EXTRACELLULAR VESICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LIQUID BIOPSY MARKET SIZE, BY EXTRACELLULAR VESICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LIQUID BIOPSY MARKET SIZE, BY EXTRACELLULAR VESICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BLOOD BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BLOOD BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BLOOD BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL LIQUID BIOPSY MARKET SIZE, BY URINE BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LIQUID BIOPSY MARKET SIZE, BY URINE BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LIQUID BIOPSY MARKET SIZE, BY URINE BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LIQUID BIOPSY MARKET SIZE, BY ASSAY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LIQUID BIOPSY MARKET SIZE, BY ASSAY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LIQUID BIOPSY MARKET SIZE, BY ASSAY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL LIQUID BIOPSY MARKET SIZE, BY MULTI-GENE PARALLEL ANALYSIS USING NGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LIQUID BIOPSY MARKET SIZE, BY MULTI-GENE PARALLEL ANALYSIS USING NGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LIQUID BIOPSY MARKET SIZE, BY MULTI-GENE PARALLEL ANALYSIS USING NGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SINGLE-GENE ANALYSIS USING PCR MICROARRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SINGLE-GENE ANALYSIS USING PCR MICROARRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SINGLE-GENE ANALYSIS USING PCR MICROARRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL LIQUID BIOPSY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL LIQUID BIOPSY MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL LIQUID BIOPSY MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LIQUID BIOPSY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LIQUID BIOPSY MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL LIQUID BIOPSY MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL LIQUID BIOPSY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL LIQUID BIOPSY MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL LIQUID BIOPSY MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL LIQUID BIOPSY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL LIQUID BIOPSY MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL LIQUID BIOPSY MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL LIQUID BIOPSY MARKET SIZE, BY NON-CANCER INDICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL LIQUID BIOPSY MARKET SIZE, BY NON-CANCER INDICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL LIQUID BIOPSY MARKET SIZE, BY NON-CANCER INDICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL LIQUID BIOPSY MARKET SIZE, BY ACADEMIC & RESEARCH CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL LIQUID BIOPSY MARKET SIZE, BY ACADEMIC & RESEARCH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL LIQUID BIOPSY MARKET SIZE, BY ACADEMIC & RESEARCH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CLINICAL DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CLINICAL DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CLINICAL DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL LIQUID BIOPSY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL LIQUID BIOPSY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL LIQUID BIOPSY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL LIQUID BIOPSY MARKET SIZE, BY PHYSICIAN'S OFFICE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL LIQUID BIOPSY MARKET SIZE, BY PHYSICIAN'S OFFICE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL LIQUID BIOPSY MARKET SIZE, BY PHYSICIAN'S OFFICE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL LIQUID BIOPSY MARKET SIZE, BY EARLY CANCER SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL LIQUID BIOPSY MARKET SIZE, BY EARLY CANCER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL LIQUID BIOPSY MARKET SIZE, BY EARLY CANCER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL LIQUID BIOPSY MARKET SIZE, BY RECURRENCE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL LIQUID BIOPSY MARKET SIZE, BY RECURRENCE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL LIQUID BIOPSY MARKET SIZE, BY RECURRENCE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL LIQUID BIOPSY MARKET SIZE, BY THERAPY SELECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL LIQUID BIOPSY MARKET SIZE, BY THERAPY SELECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL LIQUID BIOPSY MARKET SIZE, BY THERAPY SELECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TREATMENT MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TREATMENT MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TREATMENT MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL LIQUID BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS LIQUID BIOPSY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL LIQUID BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. GCC LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GCC LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 173. GCC LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 174. GCC LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. GCC LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. GCC LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 177. GCC LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 178. GCC LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 179. GCC LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 198. G7 LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. G7 LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 200. G7 LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 201. G7 LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. G7 LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 203. G7 LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 204. G7 LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 205. G7 LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 206. G7 LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 207. NATO LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. NATO LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 209. NATO LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 210. NATO LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. NATO LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. NATO LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 213. NATO LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 214. NATO LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 215. NATO LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)